302 related articles for article (PubMed ID: 34973510)
1. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.
Lasagna A; Lilleri D; Agustoni F; Percivalle E; Borgetto S; Alessio N; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Secondino S; Falzoni M; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Feb; 7(1):100359. PubMed ID: 34973510
[TBL] [Abstract][Full Text] [Related]
2. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
[TBL] [Abstract][Full Text] [Related]
3. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
[TBL] [Abstract][Full Text] [Related]
5. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Serra F; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Oct; 7(5):100574. PubMed ID: 36029652
[TBL] [Abstract][Full Text] [Related]
6. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
Front Immunol; 2022; 13():908108. PubMed ID: 35911701
[TBL] [Abstract][Full Text] [Related]
7. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.
Angyal A; Longet S; Moore SC; Payne RP; Harding A; Tipton T; Rongkard P; Ali M; Hering LM; Meardon N; Austin J; Brown R; Skelly D; Gillson N; Dobson SL; Cross A; Sandhar G; Kilby JA; Tyerman JK; Nicols AR; Spegarova JS; Mehta H; Hornsby H; Whitham R; Conlon CP; Jeffery K; Goulder P; Frater J; Dold C; Pace M; Ogbe A; Brown H; Ansari MA; Adland E; Brown A; Chand M; Shields A; Matthews PC; Hopkins S; Hall V; James W; Rowland-Jones SL; Klenerman P; Dunachie S; Richter A; Duncan CJA; Barnes E; Carroll M; Turtle L; de Silva TI;
Lancet Microbe; 2022 Jan; 3(1):e21-e31. PubMed ID: 34778853
[TBL] [Abstract][Full Text] [Related]
8. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
10. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
[TBL] [Abstract][Full Text] [Related]
11. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
13. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
[TBL] [Abstract][Full Text] [Related]
14. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
15. Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up.
Lasagna A; Cassaniti I; Arena F; Bergami F; Percivalle E; Comolli G; Sarasini A; Ferrari A; Cicognini D; Schiavo R; Lo Cascio G; Pedrazzoli P; Baldanti F
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047704
[TBL] [Abstract][Full Text] [Related]
16. Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration.
Mihaylova A; Lesichkova S; Baleva M; Nikolova-Vlahova M; Kundurzhiev T; Kolevski A; Naumova E
J Med Virol; 2023 Jan; 95(1):e28360. PubMed ID: 36448089
[TBL] [Abstract][Full Text] [Related]
17. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
[TBL] [Abstract][Full Text] [Related]
18. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.
Ruggeri EM; Nelli F; Fabbri A; Onorato A; Giannarelli D; Giron Berrios JR; Virtuoso A; Marrucci E; Mazzotta M; Schirripa M; Panichi V; Pessina G; Signorelli C; Chilelli MG; Primi F; Natoni F; Fazio S; Silvestri MA
ESMO Open; 2022 Feb; 7(1):100350. PubMed ID: 34942438
[TBL] [Abstract][Full Text] [Related]
20. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
